News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Suven Life Sciences Ltd To Present At Alzheimer's Association International Conference (AAIC)


7/11/2014 8:25:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HYDERABAD, INDIA (July 11, 2014) - Several exciting new results and data presentations from Suven’s portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at Alzheimer's Association International Conference (AAIC) being held in Copenhagen, Denmark during July 12-17, 2014

AAIC is the world's largest conference of its kind, where thousands of researchers from more than 60 countries will gather to reveal the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science. Alzheimer’s disease is one of the scourges of modern day health care which is the largest and fastest growing unmet medical need and Suven is in the forefront of developing a drug for the treatment of this debilitating disease. Alzheimer's is a dementia that causes problems with memory, thinking and behavior. Alzheimer’s is not just a memory loss as everyone thinks but Alzheimer’s kills.

Suven has excellent portfolio of new molecules through four mechanisms of action using 5-HT6, 5-HT4, H3 and Neuronal Nicotinic acetylcholine receptors for the symptomatic treatment of cognitive impairment in Alzheimer’s disease but also possibly useful in reducing the disease progression. Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on cognitive impairment and memory related disorders.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease and Parkinson's disease in addition to clinical candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at http://www.suven.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES